August 18, 2023 4:09pm
LPS (loss-per-share) releases will present challenges to share pricing with outcomes included
8/14 - Solid Biosciences (SLDB) a net loss of -$24.6 M or -$1.25 per share with a cash position of $160.2 M and a runway until 2025
- EPS concensus and revenue miss
8/14 Homology Medicine (FIXX) a net loss of -$35 M or -$0.61 per share with a cash position of $127.1 M and a runway until 2026 and seeking strategic alternatives from Cowen
- closed up +$0.01
8/14 - Brainstorm Cell Therapeutics (BCLI)a net loss of -$5.3 M or -$0.13 per share with a cash position of $.75 M (?) and a runway until Q4/23
- closed up +$0.05
8/14 - Harvard Apparatus (HRGN) - fomerly Biostage (BSTG)a net loss of -$2.6 M or -$0.43 per share with a cash position of $4.7 M and a runway until Q4/23
- closed flat $0.00
See More … Results
Earnings season has begun ... watch your portfolio as LPS (loss-per-share), concensus and revenue "numbers" can lower your sector company negatively ...
8/10 – Adverum Biotechnologies (ADVM) – a net loss of -$31.5 M or -$0.31 per share with a cash position of $141.5 M and a runway until 2025
- Closed down -$0.02
8/10 – Verve Therapeutics (VERV) – a net loss of -$85 M or -$0.60 per share with a cash position of $2.48 B and a runway until 2026
- EPS consensus and revenue beat
- Closed up +$0.478/9 –
8/9 - Ionis Pharmaceuticals (IONS) had a Q2/23 net loss of -$85 M or -$0.60 per share with a $2.4 B cash position and a runway until 2026
- EPS consensus and revenue beat
- Closed up +$0.43
8/9 – Precigen (PGEN) had a Q2/23 net loss of -$20.3 M or -$0.08 per share with a $95.6 M cash position and a runway until 2025
- Closed up +$0.02
8/8 – BioLife Solutions (BLFS) had a Q2/23 net loss of -$10.2 M or -$0.23 per share with a $48.1 cash position and a runway until 2H/2025
- EPS consensus and revenue miss
8/8 – Fate Therapeutics (FATE) had a Q2/23 net loss of -$56.29 M or -$0.54 per share with a $385 M cash position and a runway until 2025
- EPS consensus beat and revenue miss
8/8 – Sangamo Therapeutics (FATE) had a Q2/23 net loss of -$114.5 M or -$0.66 per share with a $182.1 M cash position and a runway until 2025
- EPS consensus and revenue miss
8/8 – Caribou Biosciences (CRBU) had a Q2/23 net loss of -$29.5 M or -$0.48 per share with a $293.5 M cash position (added $25 M from PFE in June) and a runway until Q4/2025
8/8 – Agenus (AGEN) had a Q2/23 net loss of -$73.4 M or -$0.20 per share with a $157.6 M cash position (received $25 m from PFE in June) and a runway until Q4/2025
- Consensus EPS and revenue beat
8/8 – bluebird bio (BLUE) had a Q2/23 net loss of -$72.98 M or -$0.67 per share with a $291 M cash position (received $25 m from PFE in June) and a runway until Q4/2024
- Consensus EPS and revenue beat
8/8 – Beam Therapeutics (BEAM) had a Q2/23 net loss of -$82.8 M or -$1.08 per share with a $1.1 B cash position and a runway until 2025
- Consensus EPS and revenue beat
8/7 – Prime Medicine (PRMC) – a net loss of -$42.4 M or -$0.47 per share with a cash position of $221.1 M and a runway until 2024
- closed down -$1.19
8/7 – AxoGen (AXGN) – a net loss of -$6.66 M or -$0.16 per share with a cash position of $23.2 M and a runway until 2025
- closed down -$0.14
8/7 – CRISPR Therapeutics (CRSP) – a net loss of -$77.7 M or -$0.98 per share with a cash position of $1,843 M and a runway until 2026
- closed down -$2.62
8/7 – Sage Therapeutics (SAGE) – a net loss of -$160.3 M or -$2.68 per share with a cash position of $1 B and a runway until 2025
- Net loss, per-share consensus and revenue misses
- share ricing drop of -$19.35
8/3 - Voyager Therapeutics (VYGR) had a Q2/23 net loss of -$22.2 M or -$0.51 per share with a $272.7 M cash position and a runway until 2026
- EPS beat and revenue estimates
- closed up +$0.31
8/3 - Alnylam Pharmaceuticals (ALNY) had a Q2/23 net loss of -$276 M or -$2.21 per share with a $206 B cash position and a solid runway
- Missed EPS and revenue estimates
- closed up +$3.09
8/3 - Compass Therapeutics (CMPS) had a Q2/23 net loss of -$11.3 M or -$0.09 per share with a $169 M cash position and a 2026 runway
- Beat Q2/22 EPS and no revenue
- closed up +$0.04
8/3 - Intellia Therapeutics (NTLA) had a Q2/23 net loss of -$123.7 M or -$1.40 per share with a $1.1 B cash position and a 2025 runway
- Missed EPS and revenue estimates
- closed down -$0.62
8/3 - Ultragenyx Pharmaceuticals (RARE) had a Q2/23 new loss of $159.8 M or -2.25 per share with a $618.4 M and a runway until 2026
- Missed EPS and revenue beat
- closed down -$1.05/2 -
8/3 - Cellectis SA (CLLS) had a Q2/23 consolidated net loss of -$18.6 M or -0.36 per share with a $89 M cash position and a runway until Q3/24
- closed down -$0.10
8/2 - Vericel (VCEL) had a Q2/23 net loss of -$5 M or -$0.11 per share with a $147 M cash position and a runway until 2026
- Surpassed EPS and revenue estimates8/2 - Blueprint Medicine (BPMC) had a Q2/23 net loss of $32.8 m or -$2.19 per share with a cash position of $1,0785.7 M and a runway until 2025
- EPS surprise and tops revenue estimate
8/2 - Editas Medicine (EDIT) had a Q2/23 net loss of -$40.29 M or -$0.50 with $480 M cash position and a runway until 2025
- EPS beat and revenue miss
8/2 - REGENXBIO (RGNX) had a Q2/23 net loss of -$72.1 m or -$1.66 per share with a $415 M cash position and a runway until 2025
- EPS miss and lower revenue numbers
- Closed down -$0.25
8/1 - UniQure NV (QURE) – a net loss of -$68.5 M or -$1.44 per share with a cash position of $628.6 M (excluded $100 M from Hemgenix, and $400 M from royalty sale) and a runway until 02.26
- Per-share net loss consensus and revenue misses
8/1 - MiMedx (MDXG) - a net income of +$1.2 M or +$0.00 pre share with a cash position of $68.7 M (L-T Debt of $48.8 M) and runway until 1/24
- Beats income, per share and revenue "numbers"
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
